T-cell interferon gamma binding in patients with dementia of the Alzheimer type

Archives of Neurology

Volumn 54, Issue 4, 1997, Pages 457-462

  Bongioanni, Paolo ^a   Boccardi, Barbara ^a   Borgna, Monica ^a   Castagna, Maura ^a   Mondino, Carlo ^b  

^a UNIVERSITY OF PISA   (Italy)

^b Ceva Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; DEMENTIA; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0031002089     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550160085021     Document Type: Article

References (62)

1. Bongioanni P. Platelet as a model in neurological studies: biochemical and clinical features. Arch Psicol Neurol Psichiatr. 1987;48:169-192.
2. Bongioanni P. Platelets as model in psychiatric studies. Neurol Psichiatr Sci Umane 1988;8:582-618.
3. Bongioanni P, Dadone F, Donato M. Human blood platelet as research tool in neuropsychopharmacology. J Neural Transm Suppl. 1991;33(suppl):65-71.
4. Adem A, Nordberg A, Bucht G, Winblad B. Extraneural cholinergic markers in Alzheimer's and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:247-257.
5. Rabey JM, Shenkman L, Gilad GM. Cholinergic muscarinic binding by human lymphocytes: changes with aging, antagonist treatment, and senile dementia of the Alzheimer type. Ann Neurol. 1986;20:628-631.
6. 3H-N-methyl-scopolamine binding in neurological patients: evidence of altered binding in Alzheimer's disease. Brain. 1991;114:1759-1770.
7. Bartha E, Szelenyi J, Szilagyi K, et al. Altered lymphocyte acetylcholinesterase activity in patients with senile dementia. Neurosci Lett. 1987;79:190-194.
8. Inestrosa NC, Alarcon R, Arriagada J, et al. Blood markers in Alzheimer's disease: subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes. J Neuroi Sci. 1994;122:1-5.
9. Itapaki S, McGeer PL, Akiyama H. Presence of T-cytotoxic suppressor and leukocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci Lett. 1988;91:259-264.
10. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988;9:339-349.
11. McGeer PL, McGeer EG, Kawamata T, Yamada T, Akiyama H. Reactions of the immune system in chronic degenerative neurological diseases. Can J Neurol Sci 1991;18:376-379.
12. Styren SD, Civin WH, Rogers J. Molecular, cellular and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol. 1990;110:93-104.
13. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's disease: selective effects on specific interleukins and interleukin receptors. Neuroscience. 1994;61:745-754.
14. Frohman EM, Frohman TC, Gupta S, de Fougerolles A, van den Noort S. Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. J Neuroi Sci. 1991;106:105-111.
15. Akiyama H, Kawamata T, Yamada T, et al. Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acte Neuropathol (Berl). 1993;85:628-634.
16. Akiyama H, Tooyama I, Kawamata T, Ikeda K, McGeer PL. Morphological diversities of CD44 positive astrocytes in the cerebral cortex of normal subjects and patients with Alzheimer's disease. Brain Res. 1993;632:249-259.
17. McGeer PL, Kawamata T, Walker DG, et al. Microglia in degenerative neurological disease. Glia. 1993;7:84-92.
18. Tollefson GD, Godes M, Warren JB, et al. Lymphopenia in primary degenerative dementia. J Psychiatr Res. 1989;23:191-199.
19. Androsova LV, Sekirina TP, Selezneva MD, Koliaskina GI, Gavrilova SI. Changes in the immunological parameters in Alzheimer's disease: their relation to disease severity. Zh Nevropatol Psikhiatr Im S S Korsakova. 1995;95:24-27.
20. Dysken MW, Minichiello MD, Hill JL, et al. Distribution of peripheral lymphocytes in Alzheimer patients and controls. J Psychiatr Res. 1992;26:213-218.
21. Leffell MS, Lumsden L, Steiger WA. An analysis of T lymphocyte subpopulations in patients with Alzheimer's disease. J Am Geriatr Soc. 1985;33:4-8.
22. Araga S, Kagimoto H, Funamoto K, Takahashi K. Lymphocyte proliferation and subpopulations in dementia of the Alzheimer type. Jpn J Med. 1990;29:572-575.
23. Ikeda T, Yamamoto K, Takahashi K, Yamada M. Immune system-associated antigens on the surface of peripheral blood lymphocytes in patients with Alzheimer's disease. Acta Psychiatr Scand. 1991;83:444-448.
24. Badalian LO, Groppa SA, Koval'chuk LV, et al. The characteristics of the immune status of patients with Alzheimer's disease. Zh Nevropatol Psikhiatr Im S S Korsakova. 1993;93:31-34.
25. Pirttiia T, Mattinen S, Frey H. The decrease of CDS-positive lymphocytes in Alzheimer's disease. J Neurol Sci. 1992;107:160-165.
26. Hu GR, Walls RS, Creasey H, McCusker E, Broe GA. Peripheral blood lymphocyte subset distribution and function in patients with Alzheimer's disease and other dementias. Aust N Z J Med. 1995;25:212-217.
27. Ikeda T, Yamamoto K, Takahashi K, Kaneyuki H, Yamada M. Interleukin-2 receptor in peripheral blood lymphocytes of Alzheimer's disease patients. Acta Psychiatr Scand. 1991;84:262-265.
28. Leonardi A, Arata L, Bino G, et al. Functional study of the T lymphocyte responsiveness in patients with dementia of the Alzheimer type. J Neuroimmunol. 1989;22:19-22.
29. Osterland CK, Louis EA. Immune reactivity in aging-autologous mixed lymphocyte responses. Gerontology. 1992;38:301-307.
30. Sigh VK, Fudenberg HH, Brown FR. Immunologic dysfunction: simultaneous study of Alzheimer's and older Down's patients. Mech Ageing Dev. 1986-87;37:257-264.
31. Torack RM. T-lymphocyte function in Alzheimer's disease. Neurosci Lett. 1986;71:365-369.
32. Nakamura K, Takeda M, Tanaka T, et al. Glial fibrillary acidic protein stimulates proliferation and immunogiobulin synthesis of lymphocytes from Alzheimer's disease patients. Methods Find Exp Clin Pharmacol. 1992;14:141-149.
33. Antonaci S, Garofalo AR, Chicco C, et al. Senile dementia of Alzheimer type: a distinct entity in the immunosenescence? J Clin Lab Anal. 1990;4:16-21.
34. +-cell-mediated suppressor activity. Neurology, 1985;35:1635-1638.
35. Araga S, Kagimoto H, Funamoto K, Takahashi K. Reduced natural killer cell activity in patients with dementia of the Alzheimer type. Acta Neurol Scand. 1991;84:259-263.
36. Singh VK. Studies of neuroimmune markers in Alzheimer's disease. Mol Neurobiol. 1994;9:73-81.
37. Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today. 1985;6:131-136.
38. Aguet M, Dembic Z, Merlin G. Molecular cloning and expression of the human interferon-γ receptor. Cell. 1988;55:273-280.
39. Novick D, Orchansky P, Revel M, Rubinstein M. The human interferon-γ receptor: purification, characterization and preparation of antibodies. J Biol Chem. 1987;262:8483-8487.
40. Fischer T, Thoma B, Scneurich P, Pfizenmaier K. Glycosylation of the human interferon-gamma receptor: N-linked carbohydrates contribute to structural heterogeneity and are required for ligand binding. J Biol Chem. 1990;265:1710-1717.
41. 125I-interferon-γ to receptors on human cells. J Biol Chem. 1985;260:1191-1198.
42. 125I-labeled recombinant human γ-interferon to receptors on WISH cells. Proc Natl Acad Sci U S A. 1984;81:5160-5167.
43. Valente G, Ozmen L, Novelli F, et al. Distribution of interferon-gamma receptor in human tissues. Eur J Immunol. 1992;22:2403-2412.
44. Faltynek CR, Princier GL. Modulation of interferon-α and interferon-γ receptor expression during T-lymphocyte activation and proliferation. J Interferon Res. 1986;6:639-653.
45. Gibbs VC, Williams SR, Gray PW, et al. The extracellular domain of the human interferon gamma receptor interacts with a species-specific signal transducer. Mol Cell Biol. 1991;11:5860-5866.
46. Fountoulakis M, Lahm HW, Maris A, et al. A 25-kDa stretch of the extracellular domain of the human interferon gamma receptor is required for full ligand binding capacity. J Biol Chem. 1991;266:14970-14977.
47. Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591-594.
48. Farrar MA, Fernandez-Luna J, Schreiber RD. Identification of two regions within the cytoplasmic domain of the human interferon-γ receptor required for function. J Biol Chem. 1991;266:19626-19635.
49. Hughes CP, Berg L, Danziger WL, Cohen LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
50. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
51. Bertouch JV, Roberts-Thompson PJ, Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. Br Med J (Clin Res Ed). 1983;286:1171-1172.
52. Faltynek CR, McCandless S, Baglioni C. Single high affinity binding of interferon-γ to receptors on human lymphoblastoid cells: internalization and inactivation of receptors. J Cell Physiol. 1985;123:459-463.
53. McPherson GA. Kinetic, EBDA, Ligand, Lowry: A Collection of Radioligand Binding Analysis Programs. Amsterdam, the Netherlands: Elsevier Science Publishers; 1985:12-43.
54. Faltynek CR, Princier GL, Ortaldo JR. Expression of IFN-α and IFN-γ receptors on normal human small resting T lymphocytes and large granular lymphocytes. J Immunol. 1986;136:4134-4138.
55. Celada A, Allen R, Esparza I, Gray PW, Schreiber RD. Demonstration and partial characterization of the interferon-gamma receptor on human mononuclear phagocytes. J Clin Invest. 1985;76:2196-2205.
56. Orchansky P, Rubinstein M, Fischer DG. The interferon-gamma receptor in human monocytes is different from one in nonhematopoietic cells. J Immunol. 1986;136:169-173.
57. Hartwig M. Immune ageing and Alzheimer's disease. Neuroreport. 1995;6:1274-1276.
58. Huberman M, Shalit F, Roth-Deri I, et al. Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol. 1994;5:147-152.
59. . 59. Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Brain Res. 1995;692:207-214.
60. McMillian M, Kong LY, Sawin SM, et al. Selective killing of cholinergic neurons by microgtial activation in basal forebrain mixed neuronal/glial cultures. Biochem Biophys Res Commun. 1995;215:572-577.
61. Meda L, Cassatella MA, Szendrei GI, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995;374:647-650.
62. Licastro F, Savorani G, Sarti G, et al. Zinc and thymic hormone-dependent immunity in normal ageing and in patients with senile dementia of the Alzheimer type. J Neuroimmunol. 1990;27:201-208.